These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22318789)

  • 1. ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk.
    Kratochvil CJ
    Am J Psychiatry; 2012 Feb; 169(2):112-4. PubMed ID: 22318789
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC
    Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encouraging news about ADHD drugs and heart risk in adults.
    Harv Ment Health Lett; 2012 Mar; 28(9):7. PubMed ID: 22474711
    [No Abstract]   [Full Text] [Related]  

  • 4. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
    Knight M
    Pediatrics; 2007 Jan; 119(1):154-5. PubMed ID: 17200281
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular effects of methylphenidate.
    Daniels SR
    J Pediatr; 2009 Jul; 155(1):A3. PubMed ID: 19559283
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR; Skimming JW; Muniz R
    Clin Pediatr (Phila); 2010 Sep; 49(9):840-51. PubMed ID: 20693523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
    Olfson M; Huang C; Gerhard T; Winterstein AG; Crystal S; Allison PD; Marcus SC
    J Am Acad Child Adolesc Psychiatry; 2012 Feb; 51(2):147-56. PubMed ID: 22265361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Joint position of the Guideline Group of the European Network for Hyperkintetic Disorders (EUNETHYDIS) and the German Central ADHD Network for ECG Recording on methylphenidate prescriptions].
    Banaschewski T;
    Z Kinder Jugendpsychiatr Psychother; 2008 Nov; 36(6):437-9. PubMed ID: 19034859
    [No Abstract]   [Full Text] [Related]  

  • 9. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.
    Vitiello B
    Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):459-74, xi. PubMed ID: 18295156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects.
    Rapport MD; Moffitt C
    Clin Psychol Rev; 2002 Nov; 22(8):1107-31. PubMed ID: 12436807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulants and sudden death: what is a physician to do?
    Wilens TE; Prince JB; Spencer TJ; Biederman J
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supraventricular tachycardia in an adolescent with attention-deficit/hyperactivity disorder (ADHD).
    Hammerness PG; Wilens TE; Berul CI; Elkort MS
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):219-220. PubMed ID: 18216716
    [No Abstract]   [Full Text] [Related]  

  • 14. Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.
    Batra AS; Alexander ME; Silka MJ
    Pediatr Cardiol; 2012 Mar; 33(3):394-401. PubMed ID: 22298228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of stimulant medications for ADHD.
    Natl Bur Econ Res Bull Aging Health; 2014; (1):1-2. PubMed ID: 25141389
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
    Winterstein AG; Gerhard T; Shuster J; Saidi A
    Pediatrics; 2009 Jul; 124(1):e75-80. PubMed ID: 19564272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.
    Vitiello B; Elliott GR; Swanson JM; Arnold LE; Hechtman L; Abikoff H; Molina BS; Wells K; Wigal T; Jensen PS; Greenhill LL; Kaltman JR; Severe JB; Odbert C; Hur K; Gibbons R
    Am J Psychiatry; 2012 Feb; 169(2):167-77. PubMed ID: 21890793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety of drugs to treat attention deficit disorder with hyperactivity].
    Péluchon R
    Soins Pediatr Pueric; 2012; (268):9. PubMed ID: 23074795
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.